Citigroup initiated coverage on Veradermics with a new price target
$MANE
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | Overweight | Cantor Fitzgerald | |
| 3/2/2026 | $85.00 | Buy | Citigroup |
| 3/2/2026 | $75.00 | Buy | Jefferies |
| 3/2/2026 | $75.00 | Outperform | Leerink Partners |
4/A - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
3 - Veradermics, Inc (0001827635) (Issuer)
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL Reid Waldman, M.D., CEO of Veradermics, will participate in a fireside chat at 4:20 p.m. ET. Jefferies Biotech on the Beach Summit on Wednesday, March 11 in Miami, FL A live webcast of the Leerink conference fireside chat will be available on the "Events" page of the "Investors" section of the
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on February 12th Markets are higher after mixed reactions to yesterday's hotter than expected Jobs Report as the Bureau of Labor Statistics reported that the U.S. economy added 130,000 jobs.Forgent Power Solutions (NYSE:FPS) is celebrating its early February IPO this morning with shares having jumped 22% since trading
This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the second half of 2026 VDPHL01, if approved, has the potential to be the first and only non-hormonal oral FDA approved treatment for men and women with pattern hair loss, a condition affecting an estimated 50 million men and 30 million women in the United States Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing
SCHEDULE 13G - Veradermics, Inc (0001827635) (Subject)
SCHEDULE 13D - Veradermics, Inc (0001827635) (Subject)
S-8 - Veradermics, Inc (0001827635) (Filer)
Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight
Jefferies initiated coverage of Veradermics with a rating of Buy and set a new price target of $75.00
Citigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00
4/A - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)